Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-Kit whereas the kinase domain mutant D816VKit is resistant

Molecular Cancer Therapeutics

Volumn 1, Issue 12, 2002, Pages 1115-1124

  Frost, Michelle J ^a,b   Ferrao, Petranel T ^a,b   Hughes, Timothy P ^b   Ashman, Leonie K ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; ISOPROTEIN; LIPOCORTIN 5; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR; TRANSACTIVATOR PROTEIN;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIVISION; CELL SEPARATION; CHEMISTRY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE VECTOR; GENETICS; HUMAN; METABOLISM; MUTATION; PHOSPHORYLATION; PROGNOSIS; PROTEIN TERTIARY STRUCTURE; RETROVIRUS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CELL SEPARATION; DNA-BINDING PROTEINS; FLOW CYTOMETRY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MICROSCOPY, FLUORESCENCE; MUTATION; PHOSPHORYLATION; PIPERAZINES; PRECIPITIN TESTS; PROGNOSIS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RETROVIRIDAE; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0038731316     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Yarden, Y., Kuang, W. J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T. J., Chen, E., Schlessinger, J., Francke, U., and Ullrich, A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J., 6: 3341-3351, 1987.
2. Qiu, F. H., Ray, P., Brown, K., Barker, P. E., Jhanwar, S., Ruddle, F. H., and Besmer, P. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family - oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J., 7: 1003-1011, 1988.
3. Rottapel, R., Reedijk, M., Williams, D. E., Lyman, S. D., Anderson, D. M., Pawson, T., and Bernstein, A. The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor. Mol. Cell. Biol., 11: 3043-3051, 1991. (Pubitemid 21895690)
4. Lev, S., Yarden, Y., and Givol, D. Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor. J. Biol. Chem., 267: 15970-15977, 1992.
5. Nocka, K., Majumder, S., Chabot, B., Ray, P., Cervone, M., Bernstein, A., and Besmer, P. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice - evidence for an impaired c-kit kinase in mutant mice. Genes Dev., 3: 816-826, 1989.
6. Ashman, L. K., Cambareri, A. C., To, L. B., Levinsky, R. J., and Juttner, C. A. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood, 78: 30-37, 1991.
7. Simmons, P. J., Aylett, G. W., Niutta, S., To, L. B., Juttner, C. A., and Ashman, L. K. c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Exp. Hematol., 22: 157-165, 1994. (Pubitemid 24118536)
8. Ishikawa, K., Komuro, T., Hirota, S., and Kitamura, Y. Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: a comparison of control and Ws/Ws mutant rats. Cell Tissue Res., 289: 137-143, 1997. (Pubitemid 27279879)
9. Ikeda, H., Kanakura, Y., Tamaki, T., Kuriu, A., Kitayama, H., Ishikawa, J., Kanayama, Y., Yonezawa, T., Tarui, S., and Griffin, J. D. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood, 78: 2962-2968, 1991.
10. Cole, S. R., Aylett, G. W., Harvey, N. L., Cambareri, A. C., and Ashman, L. K. Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukemia. Leukemia (Baltimore), 10: 288-296, 1996. (Pubitemid 26103363)
11. Butterfield, J. H., Weiler, D., Dewald, G., and Gleich, G. J. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk. Res., 12: 345-355, 1988.
12. Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., Muhammad Tunio, G., Matsuzawa, Y., Kanakura, Y., Shinomura, Y., and Kitamura, Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (Wash. DC), 279: 577-580, 1998. (Pubitemid 28067289)
13. Hibi, K., Takahashi, T., Sekido, Y., Ueda, R., Hida, T., Ariyoshi, Y., and Takagi, H. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene, 6: 2291-2296, 1991. (Pubitemid 21924076)
14. Krystal, G. W., Hines, S. J., and Organ, C. P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res., 56: 370-376, 1996.
15. Tian, Q., Frierson, H. F., Jr., Krystal, G. W., and Moskaluk, C. A. Activating c-kit gene mutations in human germ cell tumors. Am. J. Pathol., 154: 1643-1647, 1999. (Pubitemid 29262845)
16. Turner, A. M., Zsebo, K. M., Martin, F., Jacobsen, F. W., Bennett, L. G., and Broudy, V. C. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood, 80: 374-381, 1992.
17. DiPaola, R. S., Kuczynski, W. I., Onodera, K., Ratajczak, M. Z., Hijiya, N., Moore, J., and Gewirtz, A. M. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther., 4: 176-182, 1997. (Pubitemid 127667113)
18. Hines, S. J., Litz, J. S., and Krystal, G. W. Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors. Breast Cancer Res Treat., 58: 1-10, 1999. (Pubitemid 30003865)
19. Timeus, F., Crescenzio, N., Valle, P., Pistamiglio, P., Piglione, M., Garelli, E., Ricotti, E., Rocchi, P., Strippoli, P., Cordero di Montezemolo, L., Madon, E., Ramenghi, U., and Basso, G. Stem cell factor suppresses apoptosis in neuroblastoma cell lines. Exp. Hematol., 25: 1253-1260, 1997. (Pubitemid 27508873)
20. Reith, A. D., Ellis, C., Lyman, S. D., Anderson, D. M., Williams, D. E., Bernstein, A., and Pawson, T. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J., 10: 2451-2459, 1991. (Pubitemid 21905718)
21. Vandenbark, G. R., deCastro, C. M., Taylor, H., Dew-Knight, S., and Kaufman, R. E. Cloning and structural analysis of the human c-kit gene. Oncogene, 7: 1259-1266, 1992.
22. Crosier, P. S., Ricciardi, S. T., Hall, L. R., Vitas, M. R., Clark, S. C., and Crosier, K. E. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood, 82: 1151-1158, 1993. (Pubitemid 23253988)
23. Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J. H., Ashman, L. K., Kanayama, Y., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin. Investig., 92: 1736-1744, 1993. (Pubitemid 23304537)
24. Kitayama, H., Kanakura, Y., Furitsu, T., Tsujimura, T., Oritani, K., Ikeda, H., Sugahara, H., Mitsui, H., Kanayama, Y., Kitamura, Y., et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood, 85: 790-798, 1995.
25. Tsujimura, T. Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells. Pathol. Int., 46: 933-938, 1996. (Pubitemid 27029994)
26. Hashimoto, K., Tsujimura, T., Moriyama, Y., Yamatodani, A., Kimura, M., Tohya, K., Morimoto, M., Kitayama, H., Kanakura, Y., and Kitamura, Y. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am. J. Pathol., 148: 189-200, 1996. (Pubitemid 26022450)
27. Ferrao, P., Gonda, T. J., and Ashman, L. K. Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity. Blood, 90: 4539-4552, 1997. (Pubitemid 27508460)
28. Kitayama, H., Tsujimura, T., Matsumura, I., Oritani, K., Ikeda, H., Ishikawa, J., Okabe, M., Suzuki, M., Yamamura, K., Matsuzawa, Y., Kitamura, Y., and Kanakura, Y. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood, 88: 995-1004, 1996. (Pubitemid 26333324)
29. Piao, X., and Bernstein, A. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood, 87: 3117-3123, 1996. (Pubitemid 26115339)
30. Tsujimura, T., Furitsu, T., Morimoto, M., Isozaki, K., Nomura, S., Matsuzawa, Y., Kitamura, Y., and Kanakura, Y. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood, 83: 2619-2626, 1994. (Pubitemid 24135855)
31. Tsujimura, T., Furitsu, T., Morimoto, M., Kanayama, Y., Nomura, S., Matsuzawa, Y., Kitamura, Y., and Kanakura, Y. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int. Arch. Allergy Immunol., 106: 377-385, 1995.
32. Nagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., and Metcalfe, D. D. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA, 92: 10560-10564. 1995.
33. Longley, B. J., Tyrrell, L., Lu, S. Z., Ma, Y. S., Langley, K., Ding, T. G., Duffy, T., Jacobs, P., Tang, L. H., and Modlin, I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet., 12: 312-314. 1996. (Pubitemid 26080092)
34. Worobec, A. S., Semere, T., Nagata, H., and Metcalfe, D. D. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer (Phila.), 83: 2120-2129. 1998. (Pubitemid 28525393)
35. Buttner, C., Henz, B. M., Welker, P., Sepp, N. T., and Grabbe, J. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J. Investig. Dermatol., 111: 1227-1231, 1998. (Pubitemid 29115205)
36. Sperr, W. R., Walchshofer, S., Horny, H. P., Fodinger, M., Simonitsch, I., Fritsche-Polanz, R., Schwarzinger, I., Tschachler, E., Sillaber, C., Hagen, W., Geissler, K., Chott, A., Lechner, K., and Valent, P. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br. J. Haematol., 103: 740-749. 1998. (Pubitemid 28545310)
37. Longley, B. J., Jr., Metcalfe, D. D., Tharp, M., Wang, X., Tyrrell, L., Lu, S. Z., Heitjan, D., and Ma, Y. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. USA, 96: 1609-1614. 1999. (Pubitemid 29098499)
38. Akin, C., Kirshenbaum, A. S., Semere, T., Worobec, A. S., Scott, L. M., and Metcalfe, D. D. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells. B cells, and myelomonocytic cells in patients with mastocytosis. Exp. Hematol., 28: 140-147, 2000. (Pubitemid 30100820)
39. Sotlar, K., Marafioti, T., Griesser, H., Theil, J., Aepinus, C., Jaussi, R., Stein, H., Valent, P., and Horny, H. P. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol. Pathol., 53: 188-193. 2000. (Pubitemid 30603073)
40. Fritsche-Polanz, R., Jordan, J. H., Feix, A., Sperr, W. R., Sunder-Plassmann, G., Valent, P., and Fodinger, M. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br. J. Haematol., 113: 357-364, 2001. (Pubitemid 32523138)
41. Jordan, J. H., Fritsche-Polanz, R., Sperr, W. R., Mitterbauer, G., Fodinger, M., Schernthaner, G. H., Christian Bankl, H., Gebhart, W., Chott, A., Lechner, K., and Valent, P. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leuk. Res., 25: 627-634. 2001. (Pubitemid 32506769)
42. Ning, Z. Q., Li, J., and Arceci, R. J. Activating mutations of c-Kit at codon 816 confer drug resistance in human leukemia cells. Leuk. Lymphoma, 41: 513-522, 2001. (Pubitemid 32717305)
43. Ashman, L. K., Ferrao, P., Cole, S. R., and Cambareri, A. C. Effects of mutant c-kit in early myeloid cells. Leuk. Lymphoma, 37: 233-243, 2000.
44. Beghini, A., Cairoli, R., Morra, E., and Larizza, L. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol. Dis., 24: 262-270, 1998. (Pubitemid 28365743)
45. Hongyo, T., Li, T., Syaifudin, M., Baskar, R., Ikeda, H., Kanakura, Y., Aozasa, K., and Nomura, T. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res., 60: 2345-2347, 2000. (Pubitemid 30262418)
46. Tsujimura, T., Morimoto, M., Hashimoto, K., Moriyama, Y., Kitayama, H., Matsuzawa, Y., Kitamura, Y., and Kanakura, Y. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood, 87: 273-283, 1996. (Pubitemid 26011841)
47. Tsujimura, T., Kanakura, Y., and Kitamura, Y. Mechanisms of constitutive activation of c-kit receptor tyrosine kinase Leukemia (Baltimore), 11 (Suppl. 3): 396-398, 1997.
48. Kindblom, L. G., Remotti, H. E., Aldenborg, F., and Meis-Kindblom, J. M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am. J. Pathol., 152: 1259-1269, 1998. (Pubitemid 28221878)
49. Taniguchi, M., Nishida, T., Hirota, S., Isozaki, K., Ito, T., Nomura, T., Matsuda, H., and Kitamura, Y. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res., 59: 4297-300, 1999. (Pubitemid 29418746)
50. Lasota, J., Jasinski, M., Sarlomo-Rikala, M., and Miettinen, M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol., 154: 53-60, 1999. (Pubitemid 29031611)
51. Beghini, A., Tibiletti, M. G., Roversi, G., Chiaravalli, A. M., Serio, G., Capella, C., and Larizza, L. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer (Phila.), 92: 657-662, 2001. (Pubitemid 32735203)
52. Maeyama, H., Hidaka, E., Ota, H., Minami, S., Kajiyama, M., Kuraishi, A., Mori, H., Matsuda, Y., Wada, S., Sodeyama, H., Nakata, S., Kawamura, N., Hata, S., Watanabe, M., Iijima, Y., and Katsuyama, T. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology, 120: 210-215, 2001. (Pubitemid 32061885)
53. Lam, L. P., Chow, R. Y., and Berger, S. A. A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain. Biochem. J., 338: 131-138, 1999. (Pubitemid 29097295)
54. Tsujimura, T., Hashimoto, K., Kitayama, H., Ikeda, H., Sugahara, H., Matsumura, I., Kaisho, T., Terada, N., Kitamura, Y., and Kanakura, Y. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Blood, 93: 1319-1329, 1999. (Pubitemid 29076147)
55. Ma, Y., Cunningham, M. E., Wang, X., Ghosh, I., Regan, L., and Longley, B. J. Inhibition of spontaneous receptor phosphorylation by residues in a putative α-helix in the KIT intracellular juxtamembrane region. J. Biol. Chem., 274: 13399-13402, 1999.
56. Piao, X., Paulson, R., van der Geer, P., Pawson, T., and Bernstein, A. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc. Natl. Acad. Sci. USA, 93: 14665-14669, 1996.
57. Kozlowski, M., Larose, L., Lee, F., Le, D. M., Rottapel, R., and Siminovitch, K. A. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol. Cell. Biol., 18: 2089-2099, 1998. (Pubitemid 28152658)
58. Chian, R., Young, S., Danilkovitch-Miagkova, A., Ronnstrand, L., Leonard, E., Ferrao, P., Ashman, L., and Linnekin, D. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood, 98: 1365-1373, 2001.
59. Ning, Z. Q., Li, J., and Arceci, R. J. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood, 97: 3559-3567, 2001.
60. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B. J., and Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56: 100-104, 1996.
61. Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., and Druker, B. J. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood, 90: 4947-4952, 1997. (Pubitemid 28007210)
62. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., and Lydon, N. B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther., 295: 139-145, 2000.
63. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001. (Pubitemid 32267972)
64. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344: 1038-1042. 2001. (Pubitemid 32267973)
65. Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S., Capdeville, R., Dimitrijevic, S., Druker, B., and Demetri, G. D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med., 344: 1052-1056, 2001.
66. van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., Silberman, S., and Nielsen, O. S. Safety and efficacy of Imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet, 358: 1421-1423, 2001.
67. Sarlomo-Rikala, M., Kovatich, A. J., Barusevicius, A., and Miettinen, M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod. Pathol., 11: 728-734. 1998. (Pubitemid 28381606)
68. Krystal, G. W., Honsawek, S., Litz, J., and Buchdunger, E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res., 6: 3319-3326, 2000. (Pubitemid 30637763)
69. Wang, W. L., Healy, M. E., Sattler, M., Verma, S., Lin, J., Maulik, G., Stiles, C. D., Griffin, J. D., Johnson, B. E., and Salgia, R. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene, 19: 3521-3528, 2000. (Pubitemid 30487449)
70. Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., and Zigler, A. J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, 96: 925-932, 2000. (Pubitemid 30618049)
71. Ma, Y., Zeng, S., Metcalfe, D. D., Akin, C., Dimitrijevic, S., Butterfield, J. H., McMahon, G., and Longley, B. J. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood, 99: 1741-1744, 2002. (Pubitemid 34533049)
72. Caruana, G., Cambareri, A. C., and Ashman, L. K. Isoforms of c-KIT differ in activation of signaling pathways and transformation of NIH3T3 fibroblasts. Oncogene, 18: 5573-5581, 1999. (Pubitemid 29481504)
73. Aylett G., Cole, S. R., Caruana, G., Ashman, L. K. Specificity and functional effects of mAb to c-Kit protein (SCF receptor). In: Schlossman, S. F., Boumsell, L., Gilks, W., Harlan, J. M., Kishimoto, T., Morimoto, C., Ritz, J., Shaw, S., Silverstein, R., Springer, T., Tedder, T. F., and Todd, R. F. (eds.). Leukocyte Typing V- White Cell Differentiation Antigens, Proceedings of the Fifth International Workshop and Conference, Vol. 2, pp. 1917-1920. Oxford: Oxford University Press, 1995.
74. Dexter, T. M., Garland, J., Scott, D., Scolnick, E., and Metcalf, D. Growth of factor-dependent hemopoietic precursor cell lines. J. Exp. Med., 152: 1036-1047, 1980. (Pubitemid 10010885)
75. Longley, B. J., Reguera, M. J., and Ma, Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk. Res., 25: 571-576, 2001. (Pubitemid 32506764)
76. Deininger, M. W., Goldman, J. M., Lydon, N., Melo, J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90: 3691-3698, 1997. (Pubitemid 27473440)
77. Gambacorti-Passerini, C., Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., Biondi, A., Corneo, G. M., Belotti, D., Pogliani, E., and Lydon, N. B. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis., 23: 380-394, 1998.
78. Ning, Z. Q., Li, J., McGuinness, M., and Arceci, R. J. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity. Oncogene, 20: 4528-4536, 2001. (Pubitemid 32772435)
79. Blume-Jensen, P., Janknecht, R., and Hunter, T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol., 8: 779-782, 1998. (Pubitemid 28301165)
80. Tuveson, D. A., Willis, N. A., Jacks, T., Griffin, J. D., Singer, S., Fletcher, C. D., Fletcher, J. A., and Demetri, G. D. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 20: 5054-5058, 2001. (Pubitemid 32769795)
81. Pignon, J. M., Giraudier, S., Duquesnoy, P., Jouault, H., Imbert, M., Vainchenker, W., Vernant, J. P., and Tulliez, M. A new c-kit mutation in a case of aggressive mast cell disease. Br. J. Haematol., 96: 374-376, 1997. (Pubitemid 27077375)
82. Nakata, Y., Kimura, A., Katoh, O., Kawaishi, K., Hyodo, H., Abe, K., Kuramoto, A., and Satow, Y. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br. J. Haematol., 91: 661-663, 1995.
83. Hirota, S., Nishida, T., Isozaki, K., Taniguchi, M., Nakamura, J., Okazaki, T., and Kitamura, Y. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J. Pathol., 193: 505-510, 2001. (Pubitemid 32266820)